Abstract: A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.

Abstract: An oral care composition, including a non-aqueous dispersant and a fatty acid structure-building agent.

Abstract: Combinations of a zinc salt and an isothiocyanate are provided, and more particularly to a consumer acceptable oral composition containing such combination which is effective in the reduction of volatile sulfur compounds (VSCs).

Abstract: An oral care composition, including a non-aqueous dispersant and an amphiphilic copolymer structure-building agent.

Abstract: The present invention relates to pharmaceutical compositions for a combination therapy with a corticosteroid and exosomes. By means of the combination therapy diseases such as osteoarthritis, arthritis and/or degenerative spinal diseases can be treated.

Abstract: Enhanced delivery of compositions for treatment of skin tissue with photoactive plasmonic nanoparticles and light, with embodiments relating to delivery devices using, for example, ultrasound. Treatments are useful for cosmetic, diagnostic and therapeutic applications.

Abstract: Compositions and methods are provided for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject comprising: one or more pharmacologically active agents that causes at least one of IKr channel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-go-related gene (hERG); and one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the pharmacologically active agent.

Abstract: The present disclosure relates to a method for preparing a novel sugar alcohol with a modified, that is, increased or decreased surface area and/or porosity while having flowability as a solid phase, and also to a sugar alcohol prepared by the preparing method or a pharmaceutical composition, a cosmetic composition, a food composition and a feed composition, comprising the sugar alcohol as a carrier. According to the present disclosure, the method for preparing a sugar alcohol comprises: (A) reacting the sugar alcohol in a solid state with a solvent (S), wherein the solid state sugar alcohol is not dissolved by the solvent (S) and is reacted with the solvent (S) as a solid dispersion; and (B) removing the solvent (S) therefrom. The sugar alcohol prepared by the preparing method of the present disclosure has a modified, that is, increased or decreased surface area and/or porosity in comparison with a conventional sugar alcohol.

Abstract: An anti-microbial formulation for seed and crop application includes about 170 ppm hypochlorous acid; about 25 ppm hypochlorite ion; about 2.5 ppm ozone; about 2.5 ppm chlorine dioxide; between about 10 ppm and about 100,000 ppm alkyl polyglycoside; and a remainder of water. A method of manipulating the pH of the formulation and a method of treating seeds and crops with the formulation to restrict or eliminate microbial growth and proliferation is also described herein.

Abstract: The method for treating cardiovascular disease relates to stopping growth of an atherosclerotic plaque or lesion. A therapeutically effective amount of a pharmaceutically acceptable gallium compound is administered to an inflammation site in an artery with a lesion with microcalcifications. Gallium ions bind to the lesion. The proper amount of gallium compound delivered to the lesion disrupts a calcification process at the inflammation site. The gallium ions bind to calcium hydroxyapatites in microcalcifications so that the microcalcifications can no longer differentiate into early phase osteoblasts. The gallium integrated into the calcium structures at the inflammation site has a lasting effect to reduce atherosclerotic plaques.

Abstract: Methods and formulations for controlling parasitic insect infestations, such as human lice infestations, on textiles. In one embodiment, a method includes applying an anti-parasitic formulation to a textile in need of treatment. In one embodiment, an anti-lice formulation includes an effective amount of at least one spinosyn, such as spinosad. In one embodiment, the anti-lice formulation is at least one of an aqueous suspension and an aqueous solution. The anti-lice formulation may also include one or more additional active ingredients and one or more carriers. The anti-lice formulation has parasiticidal activity when applied to a textile. For example, in one embodiment the anti-lice formulation is formulated to produce 100% adulticidal, nymphicidal, and ovicidal activity when applied to a textile in need of treatment.

Abstract: The present invention includes a composition and method for treating a glioblastoma in a human or animal subject comprising the steps of: identifying the human or animal subject in need of treatment of a glioblastoma, wherein the human or animal is no longer responsive to at least one of chemotherapy, surgery, or radiation therapy; and administering to the human or animal subject a therapeutically effective amount of a composition comprising: an amount of a curcumin or curcuminoids in one or more liposomes, or curcumin or curcuminoids and empty liposomes and administered prior to, concomitantly, or after administration of the curcumin or curcuminoids, that is effective for treating the glioblastoma, wherein the liposomal curcumin or curcuminoids, or empty liposomes, eliminate the QT prolongation caused by the curcumin or curcuminoids; and at least one chemotherapeutic agent that is synergistic with curcumin to treat the glioblastoma.

Abstract: A mixture, comprising at least four different chemical compounds, selected from the group consisting of calcium ascorbate, tocopherol acetate, coenzyme Q10, eicosapentaenoic acid, usnic acid, L-carnitine fumarate and norspermidine, is used in dental health compositions. The mixture when used for dental hygiene has bactericidal and bacteriostatic effectiveness against S. mutans and S. sorbinus.

Abstract: The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.

Abstract: The invention relates to a composition for the detection of tooth demineralization. More specifically, the invention concerns a composition comprising a complex capable of producing an optical signal characteristic of the presence of free ions, the pharmaceutical uses of such a composition, and methods and a kit for the detection of active demineralization at tooth surfaces using such a composition.

Abstract: This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth, including killing bacterial biofilms.

Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.

Abstract: The present invention relates to methods for treating microbial infections on the surfaces of an implant or other surfaces near an implant in a patient. In particular, the methods are useful for treating biofilm infections. The methods include the use of minimally invasive techniques, including the use of ultra sound for facilitating the detection of biofilm infections on the implant or other surface of a patient and destroying the infection by administering an anthocyanin or an anthocyanidin or metabolite thereof. In particular, the administration of protocatechuic acid (PCA) or 2,4,6 trihydroxybenzaldehyde (2,4,6 THBA) for the treatment of an infected implant or other surface of a patient is described herein.

Abstract: The present invention provides a pharmaceutical composition comprising at least one hydrophobic camptothecin derivative or a pharmaceutically acceptable salt of said derivative and a polyethylene glycol (PEG) conjugated phospholipid. Also provided is a method to inhibit cancer cells in a subject in need thereof by administering the pharmaceutical composition of the present invention.

Abstract: An object of the present invention is to provide an oxaliplatin-encapsulating liposome aqueous dispersion that has excellent long-term storage stability. The present invention provides an aqueous dispersion of liposomes encapsulating oxaliplatin, the oxaliplatin-encapsulating liposome aqueous dispersion containing 2-morpholinoethanesulfonic acid in an external aqueous phase.